106 related articles for article (PubMed ID: 21352693)
21. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas.
Moore LM; Holmes KM; Smith SM; Wu Y; Tchougounova E; Uhrbom L; Sawaya R; Bruner JM; Fuller GN; Zhang W
Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16675-9. PubMed ID: 19805356
[TBL] [Abstract][Full Text] [Related]
22. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo.
Huse JT; Brennan C; Hambardzumyan D; Wee B; Pena J; Rouhanifard SH; Sohn-Lee C; le Sage C; Agami R; Tuschl T; Holland EC
Genes Dev; 2009 Jun; 23(11):1327-37. PubMed ID: 19487573
[TBL] [Abstract][Full Text] [Related]
23. Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma.
Lindberg N; Kastemar M; Olofsson T; Smits A; Uhrbom L
Oncogene; 2009 Jun; 28(23):2266-75. PubMed ID: 19421151
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures.
Ropolo M; Daga A; Griffero F; Foresta M; Casartelli G; Zunino A; Poggi A; Cappelli E; Zona G; Spaziante R; Corte G; Frosina G
Mol Cancer Res; 2009 Mar; 7(3):383-92. PubMed ID: 19276180
[TBL] [Abstract][Full Text] [Related]
25. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.
Lin Y; Jiang T; Zhou K; Xu L; Chen B; Li G; Qiu X; Jiang T; Zhang W; Song SW
Neuro Oncol; 2009 Oct; 11(5):468-76. PubMed ID: 19164435
[TBL] [Abstract][Full Text] [Related]
26. Genetically engineered mouse models of brain cancer and the promise of preclinical testing.
Huse JT; Holland EC
Brain Pathol; 2009 Jan; 19(1):132-43. PubMed ID: 19076778
[TBL] [Abstract][Full Text] [Related]
27. Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth.
Binning MJ; Niazi T; Pedone CA; Lal B; Eberhart CG; Kim KJ; Laterra J; Fults DW
Cancer Res; 2008 Oct; 68(19):7838-45. PubMed ID: 18829539
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
Vogelbaum MA; Berkey B; Peereboom D; Macdonald D; Giannini C; Suh JH; Jenkins R; Herman J; Brown P; Blumenthal DT; Biggs C; Schultz C; Mehta M
Neuro Oncol; 2009 Apr; 11(2):167-75. PubMed ID: 18779504
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Cancer Genome Atlas Research Network
Nature; 2008 Oct; 455(7216):1061-8. PubMed ID: 18772890
[TBL] [Abstract][Full Text] [Related]
30. Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype.
McMurray HR; Sampson ER; Compitello G; Kinsey C; Newman L; Smith B; Chen SR; Klebanov L; Salzman P; Yakovlev A; Land H
Nature; 2008 Jun; 453(7198):1112-6. PubMed ID: 18500333
[TBL] [Abstract][Full Text] [Related]
31. Constitutive activation of Raf-1 induces glioma formation in mice.
Lyustikman Y; Momota H; Pao W; Holland EC
Neoplasia; 2008 May; 10(5):501-10. PubMed ID: 18472967
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.
Quon H; Abdulkarim B
Cochrane Database Syst Rev; 2008 Apr; (2):CD007104. PubMed ID: 18425979
[TBL] [Abstract][Full Text] [Related]
33. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.
Reardon DA; Wen PY; Desjardins A; Batchelor TT; Vredenburgh JJ
Expert Opin Biol Ther; 2008 Apr; 8(4):541-53. PubMed ID: 18352856
[TBL] [Abstract][Full Text] [Related]
34. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Stommel JM; Kimmelman AC; Ying H; Nabioullin R; Ponugoti AH; Wiedemeyer R; Stegh AH; Bradner JE; Ligon KL; Brennan C; Chin L; DePinho RA
Science; 2007 Oct; 318(5848):287-90. PubMed ID: 17872411
[TBL] [Abstract][Full Text] [Related]
35. Insulin-like growth factor binding protein 2 promotes glioma development and progression.
Dunlap SM; Celestino J; Wang H; Jiang R; Holland EC; Fuller GN; Zhang W
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11736-41. PubMed ID: 17606927
[TBL] [Abstract][Full Text] [Related]
36. Apoptosis suppression by somatic cell transfer of Bcl-2 promotes Sonic hedgehog-dependent medulloblastoma formation in mice.
McCall TD; Pedone CA; Fults DW
Cancer Res; 2007 Jun; 67(11):5179-85. PubMed ID: 17545597
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of disease: genetic predictors of response to treatment in brain tumors.
Collins VP
Nat Clin Pract Oncol; 2007 Jun; 4(6):362-74. PubMed ID: 17534392
[TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
McConville P; Hambardzumyan D; Moody JB; Leopold WR; Kreger AR; Woolliscroft MJ; Rehemtulla A; Ross BD; Holland EC
Clin Cancer Res; 2007 May; 13(10):2897-904. PubMed ID: 17504989
[TBL] [Abstract][Full Text] [Related]
39. Genetic pathways to primary and secondary glioblastoma.
Ohgaki H; Kleihues P
Am J Pathol; 2007 May; 170(5):1445-53. PubMed ID: 17456751
[TBL] [Abstract][Full Text] [Related]
40. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.
Mehrian-Shai R; Chen CD; Shi T; Horvath S; Nelson SF; Reichardt JK; Sawyers CL
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5563-8. PubMed ID: 17372210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
